Kamada (NASDAQ:KMDA) Posts Earnings Results, Misses Estimates By $0.05 EPS

Kamada (NASDAQ:KMDA) announced its earnings results on Wednesday. The biotechnology company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.12 by ($0.05), FiscalAI reports. The company had revenue of $45.24 million during the quarter, compared to the consensus estimate of $46.72 million. Kamada had a net margin of 11.19% and a return on equity of 7.72%.

Here are the key takeaways from Kamada’s conference call:

• Kamada reiterated full-year 2026 guidance for $200 million-$205 million in revenue and $50 million-$53 million in adjusted EBITDA, saying the outlook is based on organic growth only and implies stronger results in the back half of the year.
• First-quarter revenue was $42.5 million, up 3% year over year, with growth driven mainly by KEDRAB and the distribution segment. A temporary shipment delay reduced Q1 revenue by about $2.4 million, but the order was already delivered in April.
• Management said demand remains strong for key products, especially KEDRAB, which is seeing increased end-user utilization in the U.S. and international markets, and VARIZIG, which is benefiting from product awareness and more chickenpox outbreaks.
• The company is expanding its distribution and biosimilars business, with two additional biosimilars expected to launch in Israel by late Q2/early Q3 and a target of roughly 45 products in the Israeli portfolio by year-end. Management also expects biosimilar sales could reach $15 million-$20 million annually over the next four to five years.
• Kamada said its newly FDA-approved San Antonio plasma center is cleared to begin commercial normal source plasma sales in the second half of 2026, and both the Houston and San Antonio centers are expected to reach planned capacity toward end-2027/early-2028. The company also noted it remains active on business development and M&A to add products and synergies.

Kamada Stock Performance

Shares of Kamada stock traded up $0.16 on Thursday, hitting $8.02. The company had a trading volume of 68,031 shares, compared to its average volume of 68,498. The stock has a 50 day moving average of $8.44 and a 200-day moving average of $7.88. The stock has a market capitalization of $461.23 million, a price-to-earnings ratio of 22.91, a P/E/G ratio of 0.64 and a beta of 0.86. Kamada has a 1 year low of $6.50 and a 1 year high of $9.35.

Kamada Dividend Announcement

The firm also recently disclosed an annual dividend, which was paid on Tuesday, April 7th. Shareholders of record on Monday, March 23rd were paid a $0.25 dividend. This represents a dividend yield of 305.0%. The ex-dividend date of this dividend was Monday, March 23rd. Kamada’s dividend payout ratio (DPR) is 54.29%.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on KMDA shares. Weiss Ratings restated a “buy (b-)” rating on shares of Kamada in a research report on Thursday, January 22nd. Stifel Nicolaus set a $11.00 price objective on shares of Kamada in a research report on Wednesday, March 11th. Wall Street Zen downgraded shares of Kamada from a “strong-buy” rating to a “buy” rating in a research note on Saturday, March 14th. Finally, Benchmark restated a “buy” rating on shares of Kamada in a report on Thursday, March 12th. Three investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $13.00.

Institutional Investors Weigh In On Kamada

Several large investors have recently made changes to their positions in KMDA. Marshall Wace LLP increased its holdings in Kamada by 25.9% in the 4th quarter. Marshall Wace LLP now owns 196,954 shares of the biotechnology company’s stock worth $1,390,000 after acquiring an additional 40,514 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Kamada by 43.3% in the 4th quarter. Goldman Sachs Group Inc. now owns 167,521 shares of the biotechnology company’s stock worth $1,183,000 after purchasing an additional 50,608 shares in the last quarter. Two Sigma Investments LP raised its stake in shares of Kamada by 4.3% during the third quarter. Two Sigma Investments LP now owns 109,589 shares of the biotechnology company’s stock worth $761,000 after acquiring an additional 4,504 shares in the last quarter. Jane Street Group LLC bought a new stake in Kamada in the first quarter worth $582,000. Finally, Bank of America Corp DE boosted its holdings in Kamada by 201.0% during the 3rd quarter. Bank of America Corp DE now owns 61,565 shares of the biotechnology company’s stock valued at $427,000 after acquiring an additional 41,111 shares during the period. 20.38% of the stock is owned by hedge funds and other institutional investors.

Kamada Company Profile

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.